Why Medical Cannabis Is So Difficult to Test for Pesticides

Medicinal cannabis is expected to meet demanding safety standards, but confirming that it is free from unacceptable pesticide residues is more complicated than placing a sample into a laboratory instrument. Cannabis flower contains a dense mixture of cannabinoids, terpenes, pigments, lipids, waxes, and other compounds. During testing, some of that chemistry can conceal the much smaller signals produced by trace contaminants.

A new study¹ accepted for publication in the Journal of Chromatography A addresses that problem by optimizing complementary methods for detecting the 105 pesticides, metabolites, and degradation products covered by the European Pharmacopoeia. The researchers combined a modified extraction process with two forms of tandem mass spectrometry, producing a validated workflow capable of measuring the targeted residues at concentrations relevant to European limits.

The achievement is significant because dependable testing is part of what separates regulated medicinal cannabis from an ordinary agricultural commodity. It also exposes a broader issue: a testing standard is only meaningful when laboratories can reliably distinguish a contaminant from the chemical background of the product being tested.

Why Cannabis Can Interfere With Its Own Safety Testing

Pesticide analysis generally begins by extracting chemical compounds from a representative sample. A laboratory then separates, identifies, and measures the targeted substances. In medicinal cannabis, however, the extraction process does not selectively remove pesticides. It also pulls large quantities of the plant’s natural compounds into the same solution.

This creates a severe imbalance. Phytocannabinoids can occur at concentrations measured in milligrams per millilitre within an extract, while the pesticides being sought may be present only at trace levels. The larger chemical background can suppress or enhance the signal of a pesticide, a phenomenon known as a matrix effect. Either outcome can distort quantification.

The researchers initially applied a protocol already validated for difficult dried herbs, teas, and extracts. It still performed poorly with medicinal cannabis. Co-extracted cannabinoids precipitated when the sample entered the liquid chromatography system, causing excessive pressure inside the instrument. Diluting the primary extract tenfold was the only tested approach that prevented this precipitation while retaining a sample large enough to support reliable homogenization.

This distinction helps explain why automated cannabis pesticide testing is only part of the solution. Faster instruments and streamlined workflows are valuable, but automation cannot compensate for sample preparation that leaves excessive interference or removes the compounds a laboratory is trying to measure.

How Researchers Cleaned Up the Cannabis Extract

The study used a modified version of QuEChERS, an extraction approach whose name refers to being quick, easy, cheap, effective, rugged, and safe. After extraction, the team compared three cleanup strategies for the liquid chromatography method: freezing the extract, treating it with PSA and calcium chloride, and using a commercial mixture called QuE Verde.

QuE Verde combines several sorbents that capture different classes of unwanted material. One targets polar acidic compounds, another removes lipids and pigments, and a carbon-based component reduces planar molecules such as chlorophylls and carotenoids. Together, they produced the cleanest extract and reduced several acidic cannabinoids substantially.

The practical improvements included:

• less interference from co-extracted plant compounds;
• more pesticide signals falling within an acceptable matrix-effect range;
• protection of the analytical equipment from cannabinoid precipitation; and
• sensitivity sufficient to assess European maximum residue limits.

Cleanup nevertheless introduced its own risk. A sorbent capable of capturing unwanted cannabis compounds may also capture a pesticide with similar chemical characteristics. QuE Verde caused an unacceptable loss of methamidophos, meaning laboratories would need to correct the result for recovery or analyze a frozen extract without the additional sorbent cleanup. Mirex also required a separate acid-cleanup procedure because cannabinoids created excessive chemical noise under the standard approach.

Why Two Testing Technologies Were Necessary

No single instrument delivered the required sensitivity across the entire pesticide list. The researchers paired liquid chromatography-tandem mass spectrometry, or LC-MS/MS, with gas chromatography-tandem mass spectrometry, or GC-MS/MS. Each platform is better suited to different chemical properties.

The LC-MS/MS method evaluated 56 pesticides and achieved qualifying detection limits for 51. Five compounds could be analyzed using liquid chromatography, but their ionization was too inefficient to reach the required thresholds. GC-MS/MS offered greater sensitivity for those pesticides. The gas chromatography method ultimately provided qualifying performance for 54 targeted analytes, with some overlap between the two platforms.

This is an important lesson for consumers and producers interpreting a certificate of analysis. A laboratory report is not automatically comprehensive simply because it contains a pesticide panel. Its value depends on which compounds were included, whether the method was validated for that particular matrix, and whether its limits of quantification were low enough to assess the applicable standard.

Different Cannabis Chemotypes Create Different Challenges

The method was optimized using THC-dominant cannabis and then tested with CBD-dominant material. Most performance characteristics were comparable, but concentrated CBD or CBDA moderately to strongly suppressed the signals of chlorpyriphos-ethyl, ethion, and piperonyl butoxide because these compounds exited the chromatography column at approximately the same time.

The researchers still achieved adequate quantification limits, but they recommended preparing calibration standards using a blank cannabis extract matched to the chemotype being tested. In simpler terms, a high-CBD sample should be measured against a comparable high-CBD background rather than assuming all cannabis flower behaves identically.

This chemotype effect points toward a future in which quality control becomes more product-specific. Flower, concentrated extracts, oils, and cannabinoid isolates contain different chemical backgrounds. As the industry develops increasingly specialized products, laboratories may need validation strategies that reflect the actual formulation rather than treating cannabis as one uniform substance. Expanding reference databases, such as the work behind the NIST mass spectral library for minor cannabinoids, can help laboratories identify more of the compounds appearing in complex samples.

What Better Pesticide Testing Means for Medical Cannabis

The study did not survey products from dispensaries, estimate contamination rates, or demonstrate that European medicinal cannabis currently contains unsafe pesticide levels. It developed and validated a way to look for specified residues. That distinction prevents a laboratory advance from being misrepresented as evidence of a consumer safety crisis.

Its regulatory importance is still substantial. The European Pharmacopoeia’s cannabis flower monograph became the legally binding standard in Europe in July 2024, placing cannabis within a harmonized pharmaceutical-quality framework. The European cannabis flower monograph sits alongside other applicable standards for herbal medicines, including pesticide-residue requirements.

Canada provides a useful comparison. Health Canada maintains a mandatory pesticide-testing program with a defined list of active ingredients and laboratory quantification limits. Its pesticide testing list and limits are periodically revised in response to industry monitoring and advances in analytical technology. The European and Canadian systems are not interchangeable, but both illustrate why analytical capability and regulation must evolve together.

There is also a commercial consequence. Reliable methods can reduce disputes between cultivators and laboratories, lower the risk of incorrect batch decisions, and make results more comparable across facilities. Producers gain clearer evidence about whether their cultivation controls are working, while patients gain greater confidence that products have been assessed using methods designed for cannabis rather than borrowed unchanged from another crop.

Better Standards Begin With Understanding the Matrix

The central contribution of this research is not simply that 105 targets can be placed on a testing list. It is the demonstration that cannabis chemistry changes how those targets must be measured. Removing too little plant material can hide pesticide signals and stress laboratory equipment. Removing too much can capture the pesticide itself. Reliable analysis depends on finding the narrow path between those failures.

The optimized workflow appears capable of meeting European requirements across THC-dominant and CBD-dominant medicinal cannabis, provided laboratories account for known exceptions and use both analytical platforms. The same principles may also help with other chemically complex medicinal herbs and extracts.

As medicinal cannabis moves further into regulated healthcare, quality cannot rest solely on cultivation claims or a generic laboratory certificate. It requires validated methods that acknowledge the product’s chemistry, specify what can be detected, and disclose where limitations remain. That less visible analytical infrastructure may ultimately be one of the most important technologies supporting a trustworthy medical cannabis market.

References:

^{1. Schusterova, D., Mraz, P., Benes, F., Drabova, L., Kocourek, V., & Hajslova, J. (2026). Optimization of analytical methods for the determination of pesticide residues in medicinal cannabis according to the European Pharmacopoeia. Journal of Chromatography A, 467403. https://doi.org/10.1016/j.chroma.2026.467403}